We are live on
!
Find out more
IHM
Iguana Healthcare Management Portfolio holdings
AUM
$152M
1-Year Est. Return
48.74%
This Fund
S&P 500
This Quarter
Est. Return
+8.86%
1 Year Est. Return
+48.74%
3 Year Est. Return
+142.13%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$152M
AUM Growth
-$1.54M
(-1%)
Cap. Flow
+$1.94M
Cap. Flow
% of AUM
1.28%
Top 10 Holdings %
Top 10 Hldgs %
37.96%
Holding
86
New
25
Increased
15
Reduced
14
Closed
24
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ZSAN
Zosano Pharma Corporation
ZSAN
|
+$4.78M |
| 2 |
SHPG
Shire pic
SHPG
|
+$3.44M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$3.29M |
| 4 |
Centene
CNC
|
+$3.13M |
| 5 |
Labcorp
LH
|
+$2.99M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$7.83M |
| 2 |
AERI
Aerie Pharmaceuticals
AERI
|
+$5.08M |
| 3 |
AbbVie
ABBV
|
+$4.84M |
| 4 |
ESPR
Esperion Therapeutics
ESPR
|
+$4.77M |
| 5 |
KTWO
K2M Group Holdings, Inc
KTWO
|
+$2.97M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 77.97% |
| 2 | Energy | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$774B
| $13.2M | 8.66% |
+50,000
| New | +$13.6M |
|
|
ESPR
2
DELISTED
Esperion Therapeutics
ESPR
| $7.23M | 4.76% |
100,000
-65,000
| -39% | -$4.77M |
|
|
IMMU
3
DELISTED
Immunomedics Inc
IMMU
| $5.84M | 3.84% |
400,000
-50,000
| -11% | -$817K |
|
|
GBT
4
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $5.55M | 3.65% |
115,000
-10,000
| -8% | -$558K |
|
5
Humana
HUM
$48B
| $5.38M | 3.54% |
20,000
-2,500
| -11% | -$677K |
|
6
Biogen
BIIB
$30.4B
| $4.79M | 3.15% |
17,500
-4,500
| -20% | -$1.4M |
|
7
Merck
MRK
$315B
| $4.36M | 2.87% |
83,840
| – | – |
|
|
ARNA
8
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $3.95M | 2.6% |
100,000
+50,000
| +100% | +$1.94M |
|
|
SHPG
9
DELISTED
Shire pic
SHPG
| $3.73M | 2.46% |
+25,000
| New | +$3.44M |
|
|
CLVS
10
DELISTED
Clovis Oncology, Inc.
CLVS
| $3.7M | 2.43% |
70,000
+10,000
| +17% | +$583K |
|
|
ESPR
11
PUT
DELISTED
Esperion Therapeutics
ESPR
| $3.62M | 2.38% |
+50,000
| New | +$3.67M |
|
12
AnaptysBio
ANAB
$1.72B
| $3.38M | 2.23% |
32,500
-7,500
| -19% | -$845K |
|
13
Cigna
CI
$74.5B
| $3.35M | 2.21% |
20,000
-5,000
| -20% | -$972K |
|
14
Viatris
VTRS
$20.1B
| $3.29M | 2.17% |
80,000
+40,000
| +100% | +$1.71M |
|
|
15
Centene
CNC
$32.8B
| $3.21M | 2.11% |
+60,000
| New | +$3.13M |
|
16
Bristol-Myers Squibb
BMY
$124B
| $3.16M | 2.08% |
50,000
| – | – |
|
|
ALXN
17
DELISTED
Alexion Pharmaceuticals
ALXN
| $3.06M | 2.02% |
+27,500
| New | +$3.29M |
|
18
Ultragenyx Pharmaceutical
RARE
$2.88B
| $3.06M | 2.01% |
60,000
+10,000
| +20% | +$504K |
|
19
Abbott
ABT
$175B
| $3M | 1.97% |
50,000
-25,000
| -33% | -$1.51M |
|
|
20
Labcorp
LH
$23.2B
| $2.83M | 1.86% |
+20,370
| New | +$2.99M |
|
21
ADMA Biologics
ADMA
$2.02B
| $2.76M | 1.82% |
600,000
| – | – |
|
22
DexCom
DXCM
$29.6B
| $2.6M | 1.71% |
+140,000
| New | +$2.07M |
|
23
Gyre Therapeutics
GYRE
$675M
| $2.58M | 1.7% |
+13,333
| New | +$2.49M |
|
|
TSRO
24
DELISTED
TESARO, Inc.
TSRO
| $2.57M | 1.69% |
45,000
+10,000
| +29% | +$643K |
|
|
ZSAN
25
DELISTED
Zosano Pharma Corporation
ZSAN
| $2.52M | 1.66% |
+14,286
| New | +$4.78M |
|
Similar funds
HWP
PAM
USG2
LCM
FPF
FIAS
CII
OPWM
Iguana Healthcare Management's Q1 2018 Portfolio in Review
As of Q1 2018, Iguana Healthcare Management held 86 positions worth $152M, down 1% from $154M the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Iguana Healthcare Management's Q1 2018 filing shows 25 new, 15 increased, 14 reduced and 24 closed positions. Its largest new stake was Zosano Pharma Corporation: 14,286 shares worth $2.52M. The largest sale was Celgene Corp, an estimated $7.83M.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 82% a quarter earlier, followed by Energy.
- Iguana Healthcare Management's largest Q1 2018 buy was Zosano Pharma Corporation: 14,286 shares worth $2.52M.
- Iguana Healthcare Management added most to Arena Pharmaceuticals Inc in Q1 2018, an estimated $1.94M increase.
- Iguana Healthcare Management's biggest Q1 2018 reduction was Esperion Therapeutics, cutting an estimated $4.77M.
- Iguana Healthcare Management fully exited Celgene Corp in Q1 2018, selling an estimated $7.83M.
- Iguana Healthcare Management's ten largest holdings make up 38% of its $152M portfolio in Q1 2018.
- Iguana Healthcare Management opened 25 new positions and closed 24 in Q1 2018.
- Iguana Healthcare Management's portfolio value fell 1% quarter-over-quarter to $152M.
Based on Iguana Healthcare Management's 13F filing for Q1 2018, filed 15 May 2018.